Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
41.75
+1.75 (4.38%)
Mar 16, 2026, 4:00 PM EDT - Market closed
Oruka Therapeutics Analyst Ratings
Total Analysts
12
Consensus Rating
Strong Buy
Price Target
$57.25
Upside
+37.13%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $58 → $86 | Buy | Maintains | $58 → $86 | +105.99% | Mar 16, 2026 |
| Barclays | Barclays | Buy Maintains $48 → $50 | Buy | Maintains | $48 → $50 | +19.76% | Mar 13, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +74.85% | Mar 13, 2026 |
| Stifel | Stifel | Strong Buy Maintains $47 → $72 | Strong Buy | Maintains | $47 → $72 | +72.46% | Mar 13, 2026 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +43.71% | Mar 13, 2026 |
| Wedbush | Wedbush | Buy Reiterates $45 | Buy | Reiterates | $45 | +7.78% | Mar 13, 2026 |
| Wedbush | Wedbush | Buy Maintains $42 → $45 | Buy | Maintains | $42 → $45 | +7.78% | Jan 13, 2026 |
| BTIG | BTIG | Strong Buy Maintains $63 → $73 | Strong Buy | Maintains | $63 → $73 | +74.85% | Jan 12, 2026 |
| UBS | UBS | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +19.76% | Jan 7, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $75 | Buy | Initiates | $75 | +79.64% | Dec 18, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +7.78% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy Maintains $56 → $63 | Strong Buy | Maintains | $56 → $63 | +50.90% | Nov 13, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +43.71% | Oct 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $40 | Strong Buy | Maintains | $45 → $40 | -4.19% | Oct 27, 2025 |
| Barclays | Barclays | Buy Initiates $48 | Buy | Initiates | $48 | +14.97% | Oct 13, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +34.13% | Sep 29, 2025 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.